Human sucrase-isomaltase / SI

dose

75 mM sucrose for expressed-SI activity; 0.7 mM added glucose in brush-border kinetic experiments

duration

1 hour at 37 C for expressed-enzyme activity; kinetic series for product inhibition

evidence_access

Selected primary full-text sections inspected via indexed PMC page; local XML has abstract only.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

Human SI expressed in COS-1 cells; isolated human intestinal brush border

exposure_scope

Human enzyme mechanism

limitations

Glucose feedback was measured in an enzyme preparation, not demonstrated as a whole-body blood-glucose control mechanism. Selected full-text methods/results inspected; archived PubMed/PMC XML contains abstract only.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

Human SI expressed in COS-1 cells; isolated human intestinal brush border

plain_language

Cleavage of sucrose by human sucrase-isomaltase also releases fructose.

primary_references

Structure-function analysis of human sucrase-isomaltase identifies key residues required for catalytic activity. (2017). https://pubmed.ncbi.nlm.nih.gov/28522605/ DOI: 10.1074/jbc.M117.791939

route

In vitro enzyme/substrate incubation

tissue

Brush-border carbohydrate digestion

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 31–41

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · Human SI expressed in COS-1 cells; isolated human intestinal brush border · source_derived_draft · unverified_draft

## sucrose-hydrolysis-fructose Cleavage of sucrose by human sucrase-isomaltase also releases fructose. Model/species: Human SI expressed in COS-1 cells; isolated human intestinal brush border Tissue: Brush-border carbohydrate digestion Exposure: 75 mM sucrose for expressed-SI activity; 0.7 mM added glucose in brush-border kinetic experiments Route: In vitro enzyme/substrate incubation Duration: 1 hour at 37 C for expressed-enzyme activity; kinetic series for product inhibition Exposure scope: Human enzyme mechanism Limits: Glucose feedback was measured in an enzyme preparation, not demonstrated as a whole-body blood-glucose control mechanism. Selected full-text methods/results inspected; archived PubMed/PMC XML contains abstract only. Reference: Structure-function analysis of human sucrase-isomaltase identifies key residues required for catalytic activity. (2017). https://pubmed.ncbi.nlm.nih.gov/28522605/ DOI: 10.1074/jbc.M117.791939 Access: Selected primary full-text sections inspected via indexed PMC page; local XML has abstract only.

dose

75 mM sucrose for expressed-SI activity; 0.7 mM added glucose in brush-border kinetic experiments

duration

1 hour at 37 C for expressed-enzyme activity; kinetic series for product inhibition

evidence_access

Selected primary full-text sections inspected via indexed PMC page; local XML has abstract only.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

Human SI expressed in COS-1 cells; isolated human intestinal brush border

exposure_scope

Human enzyme mechanism

limitations

Glucose feedback was measured in an enzyme preparation, not demonstrated as a whole-body blood-glucose control mechanism. Selected full-text methods/results inspected; archived PubMed/PMC XML contains abstract only.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

Human SI expressed in COS-1 cells; isolated human intestinal brush border

plain_language

Human sucrase-isomaltase hydrolyzes sucrose, releasing its glucose moiety.

primary_references

Structure-function analysis of human sucrase-isomaltase identifies key residues required for catalytic activity. (2017). https://pubmed.ncbi.nlm.nih.gov/28522605/ DOI: 10.1074/jbc.M117.791939

route

In vitro enzyme/substrate incubation

tissue

Brush-border carbohydrate digestion

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 19–29

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · Human SI expressed in COS-1 cells; isolated human intestinal brush border · source_derived_draft · unverified_draft

## sucrose-hydrolysis-glucose Human sucrase-isomaltase hydrolyzes sucrose, releasing its glucose moiety. Model/species: Human SI expressed in COS-1 cells; isolated human intestinal brush border Tissue: Brush-border carbohydrate digestion Exposure: 75 mM sucrose for expressed-SI activity; 0.7 mM added glucose in brush-border kinetic experiments Route: In vitro enzyme/substrate incubation Duration: 1 hour at 37 C for expressed-enzyme activity; kinetic series for product inhibition Exposure scope: Human enzyme mechanism Limits: Glucose feedback was measured in an enzyme preparation, not demonstrated as a whole-body blood-glucose control mechanism. Selected full-text methods/results inspected; archived PubMed/PMC XML contains abstract only. Reference: Structure-function analysis of human sucrase-isomaltase identifies key residues required for catalytic activity. (2017). https://pubmed.ncbi.nlm.nih.gov/28522605/ DOI: 10.1074/jbc.M117.791939 Access: Selected primary full-text sections inspected via indexed PMC page; local XML has abstract only.

dose

75 mM sucrose for expressed-SI activity; 0.7 mM added glucose in brush-border kinetic experiments

duration

1 hour at 37 C for expressed-enzyme activity; kinetic series for product inhibition

evidence_access

Selected primary full-text sections inspected via indexed PMC page; local XML has abstract only.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

Human SI expressed in COS-1 cells; isolated human intestinal brush border

exposure_scope

Human enzyme mechanism

limitations

Glucose feedback was measured in an enzyme preparation, not demonstrated as a whole-body blood-glucose control mechanism. Selected full-text methods/results inspected; archived PubMed/PMC XML contains abstract only.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

Human SI expressed in COS-1 cells; isolated human intestinal brush border

plain_language

Adding 0.7 mM glucose partially inhibited sucrose hydrolysis in the human intestinal brush-border enzyme preparation.

primary_references

Structure-function analysis of human sucrase-isomaltase identifies key residues required for catalytic activity. (2017). https://pubmed.ncbi.nlm.nih.gov/28522605/ DOI: 10.1074/jbc.M117.791939

route

In vitro enzyme/substrate incubation

tissue

Brush-border carbohydrate digestion

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 43–53

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · Human SI expressed in COS-1 cells; isolated human intestinal brush border · source_derived_draft · unverified_draft

## sucrose-glucose-feedback Adding 0.7 mM glucose partially inhibited sucrose hydrolysis in the human intestinal brush-border enzyme preparation. Model/species: Human SI expressed in COS-1 cells; isolated human intestinal brush border Tissue: Brush-border carbohydrate digestion Exposure: 75 mM sucrose for expressed-SI activity; 0.7 mM added glucose in brush-border kinetic experiments Route: In vitro enzyme/substrate incubation Duration: 1 hour at 37 C for expressed-enzyme activity; kinetic series for product inhibition Exposure scope: Human enzyme mechanism Limits: Glucose feedback was measured in an enzyme preparation, not demonstrated as a whole-body blood-glucose control mechanism. Selected full-text methods/results inspected; archived PubMed/PMC XML contains abstract only. Reference: Structure-function analysis of human sucrase-isomaltase identifies key residues required for catalytic activity. (2017). https://pubmed.ncbi.nlm.nih.gov/28522605/ DOI: 10.1074/jbc.M117.791939 Access: Selected primary full-text sections inspected via indexed PMC page; local XML has abstract only.

availability_state

machinery_impairment Imported condition classification; unverified.

dose

50 g carbohydrate load; 200 or 50 mg acarbose

duration

Acute tolerance tests; exact sampling duration unrecovered

evidence_access

Primary abstract/metadata; unrecovered methods explicitly retained.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

Healthy human volunteers; sample size unavailable in accessed abstract

exposure_scope

Drug and nutrient interaction

limitations

Acarbose inhibits carbohydrate hydrolysis. The glucose-only comparison does not support direct blockade of glucose transport. Experimental doses are not a dosing recommendation.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

Healthy human volunteers; sample size unavailable in accessed abstract

plain_language

Acarbose 200 mg reduced blood-glucose response area by 89% after a 50 g sucrose load in healthy volunteers.

primary_references

Scope and specificity of acarbose in slowing carbohydrate absorption in man. (1981). https://pubmed.ncbi.nlm.nih.gov/7028548/ DOI: 10.2337/diab.30.11.951

route

Oral carbohydrate and drug

tissue

Carbohydrate tolerance and breath hydrogen

trigger_kind

machinery_impairment Imported condition classification; unverified.

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 199–209

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · Healthy human volunteers; sample size unavailable in accessed abstract · source_derived_draft · unverified_draft

## sucrose-acarbose-glycemia Acarbose 200 mg reduced blood-glucose response area by 89% after a 50 g sucrose load in healthy volunteers. Model/species: Healthy human volunteers; sample size unavailable in accessed abstract Tissue: Carbohydrate tolerance and breath hydrogen Exposure: 50 g carbohydrate load; 200 or 50 mg acarbose Route: Oral carbohydrate and drug Duration: Acute tolerance tests; exact sampling duration unrecovered Exposure scope: Drug and nutrient interaction Limits: Acarbose inhibits carbohydrate hydrolysis. The glucose-only comparison does not support direct blockade of glucose transport. Experimental doses are not a dosing recommendation. Reference: Scope and specificity of acarbose in slowing carbohydrate absorption in man. (1981). https://pubmed.ncbi.nlm.nih.gov/7028548/ DOI: 10.2337/diab.30.11.951 Access: Primary abstract/metadata; unrecovered methods explicitly retained.

availability_state

machinery_impairment Imported condition classification; unverified.

dose

50 g carbohydrate load; 200 or 50 mg acarbose

duration

Acute tolerance tests; exact sampling duration unrecovered

evidence_access

Primary abstract/metadata; unrecovered methods explicitly retained.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

Healthy human volunteers; sample size unavailable in accessed abstract

exposure_scope

Drug and nutrient interaction

limitations

Acarbose inhibits carbohydrate hydrolysis. The glucose-only comparison does not support direct blockade of glucose transport. Experimental doses are not a dosing recommendation.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

Healthy human volunteers; sample size unavailable in accessed abstract

plain_language

Breath hydrogen after 200 mg acarbose with 50 g sucrose indicated nearly complete sucrose malabsorption in the tolerance study.

primary_references

Scope and specificity of acarbose in slowing carbohydrate absorption in man. (1981). https://pubmed.ncbi.nlm.nih.gov/7028548/ DOI: 10.2337/diab.30.11.951

route

Oral carbohydrate and drug

tissue

Carbohydrate tolerance and breath hydrogen

trigger_kind

machinery_impairment Imported condition classification; unverified.

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 211–221

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · Healthy human volunteers; sample size unavailable in accessed abstract · source_derived_draft · unverified_draft

## sucrose-acarbose-hydrogen Breath hydrogen after 200 mg acarbose with 50 g sucrose indicated nearly complete sucrose malabsorption in the tolerance study. Model/species: Healthy human volunteers; sample size unavailable in accessed abstract Tissue: Carbohydrate tolerance and breath hydrogen Exposure: 50 g carbohydrate load; 200 or 50 mg acarbose Route: Oral carbohydrate and drug Duration: Acute tolerance tests; exact sampling duration unrecovered Exposure scope: Drug and nutrient interaction Limits: Acarbose inhibits carbohydrate hydrolysis. The glucose-only comparison does not support direct blockade of glucose transport. Experimental doses are not a dosing recommendation. Reference: Scope and specificity of acarbose in slowing carbohydrate absorption in man. (1981). https://pubmed.ncbi.nlm.nih.gov/7028548/ DOI: 10.2337/diab.30.11.951 Access: Primary abstract/metadata; unrecovered methods explicitly retained.

availability_state

machinery_impairment Imported condition classification; unverified.

dose

50 g carbohydrate load; 200 or 50 mg acarbose

duration

Acute tolerance tests; exact sampling duration unrecovered

evidence_access

Primary abstract/metadata; unrecovered methods explicitly retained.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

Healthy human volunteers; sample size unavailable in accessed abstract

exposure_scope

Drug and nutrient interaction

limitations

Acarbose inhibits carbohydrate hydrolysis. The glucose-only comparison does not support direct blockade of glucose transport. Experimental doses are not a dosing recommendation.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

Healthy human volunteers; sample size unavailable in accessed abstract

plain_language

Acarbose 50 mg still reduced the blood-glucose response to sucrose, without a significant breath-hydrogen increase.

primary_references

Scope and specificity of acarbose in slowing carbohydrate absorption in man. (1981). https://pubmed.ncbi.nlm.nih.gov/7028548/ DOI: 10.2337/diab.30.11.951

route

Oral carbohydrate and drug

tissue

Carbohydrate tolerance and breath hydrogen

trigger_kind

machinery_impairment Imported condition classification; unverified.

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 235–245

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · Healthy human volunteers; sample size unavailable in accessed abstract · source_derived_draft · unverified_draft

## sucrose-acarbose-low-dose Acarbose 50 mg still reduced the blood-glucose response to sucrose, without a significant breath-hydrogen increase. Model/species: Healthy human volunteers; sample size unavailable in accessed abstract Tissue: Carbohydrate tolerance and breath hydrogen Exposure: 50 g carbohydrate load; 200 or 50 mg acarbose Route: Oral carbohydrate and drug Duration: Acute tolerance tests; exact sampling duration unrecovered Exposure scope: Drug and nutrient interaction Limits: Acarbose inhibits carbohydrate hydrolysis. The glucose-only comparison does not support direct blockade of glucose transport. Experimental doses are not a dosing recommendation. Reference: Scope and specificity of acarbose in slowing carbohydrate absorption in man. (1981). https://pubmed.ncbi.nlm.nih.gov/7028548/ DOI: 10.2337/diab.30.11.951 Access: Primary abstract/metadata; unrecovered methods explicitly retained.

availability_state

machinery_impairment Imported condition classification; unverified.

dose

Yeast sucrase preparation, 6000 IU/mg protein; full strength and 1:10, 1:100, 1:1000 dilutions; >15 kg received 2 mL; lower-weight dose volume missing from accessed abstract

duration

Single-dose breath tests; four 10-day dose periods

evidence_access

Primary abstract/metadata; unrecovered methods explicitly retained.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial

exposure_scope

Drug rescue of human genetic digestive impairment

limitations

Enzyme replacement in diagnosed CSID, not sucrose supplementation for a nutrient deficiency. Exact sucrose challenge amount and lower-weight volume unrecovered. Vomiting did not differ; wheezing occurred in one child with asthma. Not prescribing guidance.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial

plain_language

Sacrosidase, with or without milk, reduced breath hydrogen after sucrose compared with placebo in children with CSID.

primary_references

Sacrosidase therapy for congenital sucrase-isomaltase deficiency. (1999). https://pubmed.ncbi.nlm.nih.gov/9932843/ DOI: 10.1097/00005176-199902000-00008

route

Oral enzyme with sucrose challenge or normal carbohydrate-containing diet

tissue

Intestinal sucrose handling and stool/symptom outcomes

trigger_kind

machinery_impairment Imported condition classification; unverified.

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 163–173

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · 28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial · source_derived_draft · unverified_draft

## sucrose-sacrosidase-hydrogen Sacrosidase, with or without milk, reduced breath hydrogen after sucrose compared with placebo in children with CSID. Model/species: 28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial Tissue: Intestinal sucrose handling and stool/symptom outcomes Exposure: Yeast sucrase preparation, 6000 IU/mg protein; full strength and 1:10, 1:100, 1:1000 dilutions; >15 kg received 2 mL; lower-weight dose volume missing from accessed abstract Route: Oral enzyme with sucrose challenge or normal carbohydrate-containing diet Duration: Single-dose breath tests; four 10-day dose periods Exposure scope: Drug rescue of human genetic digestive impairment Limits: Enzyme replacement in diagnosed CSID, not sucrose supplementation for a nutrient deficiency. Exact sucrose challenge amount and lower-weight volume unrecovered. Vomiting did not differ; wheezing occurred in one child with asthma. Not prescribing guidance. Reference: Sacrosidase therapy for congenital sucrase-isomaltase deficiency. (1999). https://pubmed.ncbi.nlm.nih.gov/9932843/ DOI: 10.1097/00005176-199902000-00008 Access: Primary abstract/metadata; unrecovered methods explicitly retained.

availability_state

machinery_impairment Imported condition classification; unverified.

dose

Yeast sucrase preparation, 6000 IU/mg protein; full strength and 1:10, 1:100, 1:1000 dilutions; >15 kg received 2 mL; lower-weight dose volume missing from accessed abstract

duration

Single-dose breath tests; four 10-day dose periods

evidence_access

Primary abstract/metadata; unrecovered methods explicitly retained.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial

exposure_scope

Drug rescue of human genetic digestive impairment

limitations

Enzyme replacement in diagnosed CSID, not sucrose supplementation for a nutrient deficiency. Exact sucrose challenge amount and lower-weight volume unrecovered. Vomiting did not differ; wheezing occurred in one child with asthma. Not prescribing guidance.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial

plain_language

Higher sacrosidase concentrations reduced stool frequency relative to lower concentrations during carbohydrate-containing diets in children with CSID.

primary_references

Sacrosidase therapy for congenital sucrase-isomaltase deficiency. (1999). https://pubmed.ncbi.nlm.nih.gov/9932843/ DOI: 10.1097/00005176-199902000-00008

route

Oral enzyme with sucrose challenge or normal carbohydrate-containing diet

tissue

Intestinal sucrose handling and stool/symptom outcomes

trigger_kind

machinery_impairment Imported condition classification; unverified.

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 175–185

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · 28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial · source_derived_draft · unverified_draft

## sucrose-sacrosidase-stools Higher sacrosidase concentrations reduced stool frequency relative to lower concentrations during carbohydrate-containing diets in children with CSID. Model/species: 28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial Tissue: Intestinal sucrose handling and stool/symptom outcomes Exposure: Yeast sucrase preparation, 6000 IU/mg protein; full strength and 1:10, 1:100, 1:1000 dilutions; >15 kg received 2 mL; lower-weight dose volume missing from accessed abstract Route: Oral enzyme with sucrose challenge or normal carbohydrate-containing diet Duration: Single-dose breath tests; four 10-day dose periods Exposure scope: Drug rescue of human genetic digestive impairment Limits: Enzyme replacement in diagnosed CSID, not sucrose supplementation for a nutrient deficiency. Exact sucrose challenge amount and lower-weight volume unrecovered. Vomiting did not differ; wheezing occurred in one child with asthma. Not prescribing guidance. Reference: Sacrosidase therapy for congenital sucrase-isomaltase deficiency. (1999). https://pubmed.ncbi.nlm.nih.gov/9932843/ DOI: 10.1097/00005176-199902000-00008 Access: Primary abstract/metadata; unrecovered methods explicitly retained.

availability_state

machinery_impairment Imported condition classification; unverified.

dose

Yeast sucrase preparation, 6000 IU/mg protein; full strength and 1:10, 1:100, 1:1000 dilutions; >15 kg received 2 mL; lower-weight dose volume missing from accessed abstract

duration

Single-dose breath tests; four 10-day dose periods

evidence_access

Primary abstract/metadata; unrecovered methods explicitly retained.

evidence_scope

literature_reviewed; source-specific curation

experimental_model

28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial

exposure_scope

Drug rescue of human genetic digestive impairment

limitations

Enzyme replacement in diagnosed CSID, not sucrose supplementation for a nutrient deficiency. Exact sucrose challenge amount and lower-weight volume unrecovered. Vomiting did not differ; wheezing occurred in one child with asthma. Not prescribing guidance.

nutrient_topic

Sucrose chapter; direct sucrose observations are distinguished from shared component metabolism. · Sucrose

organism

28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial

plain_language

Higher sacrosidase concentrations reduced gas, cramps and bloating during carbohydrate-containing diets in children with CSID.

primary_references

Sacrosidase therapy for congenital sucrase-isomaltase deficiency. (1999). https://pubmed.ncbi.nlm.nih.gov/9932843/ DOI: 10.1097/00005176-199902000-00008

route

Oral enzyme with sucrose challenge or normal carbohydrate-containing diet

tissue

Intestinal sucrose handling and stool/symptom outcomes

trigger_kind

machinery_impairment Imported condition classification; unverified.

Sucrose: mechanism of action and metabolic impact (2026-09-20) · lines 187–197

Original AI-assisted source-specific sucrose curation with shared canonical claims retained by identity. Primary-study citations, negative findings, exposure details and limitations preserved. Not publisher full text. · supports · 28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial · source_derived_draft · unverified_draft

## sucrose-sacrosidase-symptoms Higher sacrosidase concentrations reduced gas, cramps and bloating during carbohydrate-containing diets in children with CSID. Model/species: 28 children aged 5 months to 11 years with congenital sucrase-isomaltase deficiency; randomized double-blind trial Tissue: Intestinal sucrose handling and stool/symptom outcomes Exposure: Yeast sucrase preparation, 6000 IU/mg protein; full strength and 1:10, 1:100, 1:1000 dilutions; >15 kg received 2 mL; lower-weight dose volume missing from accessed abstract Route: Oral enzyme with sucrose challenge or normal carbohydrate-containing diet Duration: Single-dose breath tests; four 10-day dose periods Exposure scope: Drug rescue of human genetic digestive impairment Limits: Enzyme replacement in diagnosed CSID, not sucrose supplementation for a nutrient deficiency. Exact sucrose challenge amount and lower-weight volume unrecovered. Vomiting did not differ; wheezing occurred in one child with asthma. Not prescribing guidance. Reference: Sacrosidase therapy for congenital sucrase-isomaltase deficiency. (1999). https://pubmed.ncbi.nlm.nih.gov/9932843/ DOI: 10.1097/00005176-199902000-00008 Access: Primary abstract/metadata; unrecovered methods explicitly retained.